证券日报网讯 8月27日晚间，珍宝岛发布公告称，公司第五届董事会第二十六次会议审议并通过了《黑 龙江珍宝岛药业股份有限公司关于2025年半年度募集资金存放、管理与实际使用情况的专项报告》等多 项议案。 （编辑 楚丽君） ...

珍宝岛表示，净利较上年同期减少主要系本期销售规模缩减及客户延期回款信用减值损失增加所致。 北京商报讯（记者 丁宁）8月27日晚间，珍宝岛（603567）发布2025半年度报告显示，公司上半年实现 营业收入7.13亿元，同比下滑57.04%；归属净利润-7828.99万元，上年同期3.93亿元，同比由盈转亏。 ...

Core Viewpoint - The company is poised for a significant value reassessment and growth in the traditional Chinese medicine market, driven by strategic adaptations to new procurement policies and an expanding product pipeline [2][5]. Group 1: Market Trends and Company Performance - The traditional Chinese medicine market is expected to reach approximately 1 trillion yuan by 2025, with the market for traditional Chinese medicine preparations exceeding 500 billion yuan, indicating sustainable growth opportunities for the company [2]. - In the first half of 2025, the company reported revenues of 713 million yuan, reflecting resilience despite challenges such as delayed procurement timelines and declining gross margins [2]. - The company's net profit turned negative primarily due to the postponement of procurement for traditional Chinese medicine, leading to a decrease in revenue and gross profit year-on-year [2]. Group 2: Strategic Initiatives and Innovations - The company has secured multiple core products for procurement, including injectable blood stasis drugs, which are expected to cover a market share exceeding 30 billion yuan, enhancing revenue prospects for the second half of 2025 [5]. - The "Procurement 2.0 Era" aligns with the company's robust operational framework, which includes an efficient supply chain covering research, production, and distribution [5]. - The company is actively pursuing innovation in drug development, with ongoing clinical trials for new traditional Chinese medicine products and collaborations in the biopharmaceutical sector [7][9]. Group 3: E-commerce and Market Expansion - The company is strategically targeting the high-end market and grassroots healthcare institutions, leveraging its established customer and channel resources to enhance sales post-procurement [9]. - E-commerce sales in China have seen significant growth, with online pharmaceutical sales projected to reach 717.7 billion yuan in 2024, prompting the company to strengthen its online presence through strategic partnerships [10]. - The company aims to achieve online retail sales of 25 million yuan in the latter half of 2025, reflecting its commitment to expanding its e-commerce footprint [10].

[Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) This section provides important declarations from the board of directors regarding report accuracy and outlines risk statements, emphasizing forward-looking statements are not commitments [Board Statement and Profit Distribution](index=2&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%8F%8A%E8%91%A3%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E4%BF%9D%E8%AF%81%E5%8D%8A%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E5%86%85%E5%AE%B9%E7%9A%84%E7%9C%9F%E5%AE%9E%E6%80%A7%E3%80%81%E5%87%86%E7%A1%AE%E6%80%A7%E3%80%81%E5%AE%8C%E6%95%B4%E6%80%A7%EF%BC%8C%E4%B8%8D%E5%AD%98%E5%9C%A8%E8%99%9A%E5%81%87%E8%AE%B0%E8%BD%BD%E3%80%81%E8%AF%AF%E5%AF%BC%E6%80%A7%E9%99%88%E8%BF%B0%E6%88%96%E9%87%8D%E5%A4%A7%E9%81%97%E6%BC%8F%EF%BC%8C%E5%B9%B6%E6%89%BF%E6%8B%85%E4%B8%AA%E5%88%AB%E5%92%8C%E8%BF%9E%E5%B8%A6%E7%9A%84%E6%B3%95%E5%BE%8B%E8%B4%A3%E4%BB%BB) The board of directors and senior management guarantee the report's truthfulness, accuracy, and completeness, assuming legal responsibility - The board of directors and senior management guarantee the report's truthfulness, accuracy, and completeness, and assume legal responsibility[3](index=3&type=chunk) - This semi-annual report is unaudited, and the company's head, chief accountant, and head of accounting department declare the financial report is true, accurate, and complete[3](index=3&type=chunk) - There is no profit distribution plan or capital reserve to share capital conversion plan for the current reporting period[3](index=3&type=chunk) [Risk Statement and Significant Risk Disclosures](index=2&type=section&id=%E5%85%AD%E3%80%81%E5%89%8D%E7%9E%BB%E6%80%A7%E9%99%88%E8%BF%B0%E7%9A%84%E9%A3%8E%E9%99%A9%E5%A3%B0%E6%98%8E) Forward-looking statements regarding future plans and development strategies in this report do not constitute actual commitments, and investors should be aware of investment risks - Forward-looking statements do not constitute actual commitments, and investors should be aware of investment risks[3](index=3&type=chunk) - There were no particularly significant risks materially affecting the company's production and operations during the reporting period; specific risks and countermeasures are detailed in Section III[4](index=4&type=chunk) [Section I Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) This section defines key terms used throughout the report, ensuring clarity and accurate understanding of the content [Definitions of Common Terms](index=4&type=section&id=%E5%B8%B8%E7%94%A8%E8%AF%8D%E8%AF%AD%E9%87%8A%E4%B9%89) This section provides definitions for common terms used in the report, including company abbreviation, controlling shareholder, GSP, GAP, "689" quality standards, IND, SRM platform, centralized procurement policies, ADC drugs, CDE, PCT pathway, MES system, B2C, and the reporting period, to ensure accurate understanding of the report's content - The reporting period refers to January 1, 2025, to June 30, 2025[12](index=12&type=chunk) - Key terms such as the Company, controlling shareholder, GSP, GAP, "689" quality standards, and centralized procurement policies are clearly defined[12](index=12&type=chunk) [Section II Company Profile and Key Financial Indicators](index=4&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section presents the company's basic information, stock details, and a comprehensive overview of its key accounting data and financial performance [Company Basic Information](index=4&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E4%BF%A1%E6%81%AF) This section introduces the company's Chinese name, abbreviation, foreign name and acronym, and legal representative Yan Jiujiang, along with contact information for the Board Secretary Zhang Zhongfang, and the company's registered address, office address, and website Company Basic Information | Indicator | Content | | :--- | :--- | | Chinese Name | 黑龙江珍宝岛药业股份有限公司 | | Chinese Abbreviation | 珍宝岛 | | Legal Representative | 闫久江 | | Registered Address | 黑龙江省鸡西市虎林市虎林镇红星街72号 | | Office Address | 黑龙江省哈尔滨市平房区烟台一路8号 | | Company Website | http://www.zbdzy.com | [Information Disclosure and Stock Overview](index=5&type=section&id=%E5%9B%9B%E3%80%81%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E5%8F%8A%E5%A4%87%E7%BD%AE%E5%9C%B0%E7%82%B9%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5%E7%AE%80%E4%BB%8B) The company designates Shanghai Securities News, China Securities Journal, Securities Times, and Securities Daily as its information disclosure newspapers, with the semi-annual report published on www.sse.com.cn and available at the company's board office - The company's information disclosure newspapers are Shanghai Securities News, China Securities Journal, Securities Times, and Securities Daily, with the website being www.sse.com.cn[15](index=15&type=chunk) Company Stock Overview | Stock Type | Listing Exchange | Stock Abbreviation | Stock Code | | :--- | :--- | :--- | :--- | | A-share | Shanghai Stock Exchange | 珍宝岛 | 603567 | [Key Accounting Data and Financial Indicators](index=5&type=section&id=%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) During the reporting period, the company's operating revenue significantly decreased by **57.04%** to **713.41 million yuan**, with total profit, net profit attributable to parent company shareholders, and non-recurring net profit all turning from profit to loss, decreasing by **122.81%**, **119.90%**, and **123.14%** respectively, while net cash flow from operating activities turned positive and increased year-on-year, primarily due to delayed national centralized procurement for traditional Chinese medicines, reduced shipments, lower product prices, decreased sales scale, and increased credit impairment losses Key Accounting Data (January-June 2025) | Indicator | Current Period (Jan-Jun) (yuan) | Prior Year Period (yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 713,410,892.19 | 1,660,604,867.40 | -57.04 | | Total Profit | -114,408,659.28 | 501,667,245.15 | -122.81 | | Net Profit Attributable to Parent Company Shareholders | -78,289,896.49 | 393,331,967.75 | -119.90 | | Net Cash Flow from Operating Activities | -62,101,205.93 | -211

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-068 黑龙江珍宝岛药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 5 日中午 12:00 前，将关注的问题以电子邮件的 形式发送至黑龙江珍宝岛药业股份有限公司（以下简称"公司"）董事会办公室 邮箱（zbddsh@zbdzy.com），公司将结合实际情况，在信息披露允许的范围内， 就投资者普遍关注的问题在说明会上进行回复。 公司于 2025 年 8 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了 《黑龙江珍宝岛药业股份有限公司 2025 年半年度报告》全文及摘要，为便于广 大投资者更全面深入地了解公司财务状况与经营情况，公司将于 2025 年 9 月 5 日（星期五）下午 15:30-16:30 召开 2025 年半年度业绩说明会。现将有关事项 公告如下： 一、业绩说明会类型 本次业绩说明会将采用网络互动方式召开，公司将针对 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-067 黑龙江珍宝岛药业股份有限公司 关于 2025 年半年度募集资金存放、管理与实际使用 情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于核准黑龙江珍宝岛药业股份有限 公司非公开发行股票的批复》（证监许可[2021]338 号）核准，黑龙江珍宝岛药 业股份有限公司（以下简称"公司"或"珍宝岛"）非公开发行人民币普通股 （A 股）92,803,592 股，发行价格为 13.34 元/股，募集资金总额为人民币 1,237,999,917.28 元,扣除本次发行费用人民币 20,759,785.06 元（不含税） 且不包括人民币普通股（A 股）发行申购资金于冻结期间产生的利息收入后， 募集资金净额为人民币 1,217,240,132.22 元，上述募集资金已于 2021 年 10 月 22 日全部到位，中准会计师事务所（特殊普通合伙）对本次非公开发行股票募 集资金到位情况进行了验证，并出具《验 ...

Group 1 - The company reported a revenue of 713 million yuan for the first half of 2025, representing a year-on-year decline of 57.04% [1] - The net profit for the company was a loss of 78.29 million yuan, compared to a net profit of 393 million yuan in the same period last year [1]

Core Points - The company is holding a shareholders' meeting on August 28, 2025, to discuss important matters including a proposal to provide guarantees for its wholly-owned subsidiary [1][2][6] - The meeting will combine on-site and online voting, with specific time slots for registration and voting [2][3] - The proposal includes a guarantee of up to RMB 400 million for the bank financing needs of its subsidiary, Heilongjiang Zhenbao Island Pharmaceutical Trade Co., Ltd. [3][5] Meeting Details - The meeting will take place at the company's office in Harbin, with the chairman, Fang Tonghua, presiding over the session [2][3] - Shareholders must register for the meeting and provide identification and proof of shareholding [1][2] - The agenda includes the announcement of the meeting's start, introduction of major shareholders, reading of meeting rules, and voting on the proposed resolutions [2][3] Proposal for Guarantee - The company plans to provide a guarantee for its subsidiary, which has a debt-to-asset ratio exceeding 70% [3][5] - The guarantee will be effective from the approval date until the annual shareholders' meeting in 2025 [3][5] - The subsidiary's financials indicate total assets of approximately RMB 3.22 billion and total liabilities of about RMB 2.49 billion [5]

黑龙江珍宝岛药业股份有限公司 2025 年第二次临时股东会 会 议 资 料 2025.8.28 1 目录 | 2025 | 年第二次临时股东会会议须知 3 | | --- | --- | | 2025 | 年第二次临时股东会会议议程 4 | | 议案 | 1：关于为全资子公司提供担保的议案 6 | 2 2025 年第二次临时股东会会议须知 为维护全体股东的合法权益，确保股东会的正常秩序和议事效率， 根据《公司法》《上市公司股东会规则》《上海证券交易所上市公司 自律监管指引第1号——规范运作》及《公司章程》等相关规定，特 制定本次股东会须知如下： 一、会议按照法律、法规、有关规定和《公司章程》的规定进行， 参会人员应自觉维护会议秩序。 二、股东参加股东会，依法享有发言权、质询权、表决权等权利， 并应认真履行法定义务，不得侵犯其他股东的合法权益。 三、参会股东或股东代表应在2025年8月26日上午9时—11时，下 午14时—16时到黑龙江珍宝岛药业股份有限公司（以下简称"公司"） 或者通过电子邮件等形式办理参会登记。已办理参会登记的股东及股 东代表需携带身份证明、股票账户卡、授权委托书等原件于2025年8 月28 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 2025年8月20日，创达集团针对本次换股价格向下修正事项召开债券持有人会议，审议通过《关于"23创 01EB"换股价格向下修正的议案》等议案，同意本次换股价格拟修正为12.35元/股。 根据上述决议，"23创01EB"的换股价格将从13.35元/股向下修正至12.35元/股，调整后的换股价格将于 2025年8月27日生效。本次换股价格下修后，创达集团本期可交债质押专户中预备用于交换的股票数量 仍满足第一期可交债全部换股所需的股票数量。 公司将密切关注本期可交债的进展情况，并根据有关规定履行持续信息披露义务，敬请广大投资者注意 投资风险。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"）收到控股股东黑龙江创达集团有 限公司（以下简称"创达集团"）的通知，创达集团2023年面向专业投资者非公开发行可交换公司债券 （第一期）（以下简称"第一期可交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股 ...